BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage ...
Entero Therapeutics to integrate applications in planned Phase 3 study of latiglutenase for celiac disease and explore additional uses of technology in clinical trial compliance BOCA RATON, Fla., Sept ...
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (ENTO),, (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results